## Edgar Filing: NOVAVAX INC - Form 4

NOVAVAX I	INC										
Form 4	15										
August 04, 20										PPROVAL	
FORM	4 UNITE	D STATES					NGE (	COMMISSION		3235-0287	
if no longe subject to Section 16 Form 4 or Form 5 obligation may contin	Section 16.SECURITIESForm 4 orForm 5Form 5Filed pursuant to Section 16(a) of the Securities Exchange Act ofobligationsSection 17(a) of the Public Utility Holding Company Act of 1935 orsee Instruction30(h) of the Investment Company Act of 1940					e Act of 1934, f 1935 or Sectio	Expires: Estimated a burden hou response	rs per			
(Print or Type Ro	esponses)										
1. Name and Ad Glenn Grego	2. Issuer Name <b>and</b> Ticker or Trading Symbol NOVAVAX INC [NVAX]				ıg	5. Relationship of Reporting Person(s) to Issuer					
(Last)	(First)	(Middle)	3. Date of	Earliest Tr	ansaction			(Chec	k all applicable	e)	
				(Month/Day/Year) 07/31/2015				Director 10% Owner X Officer (give title Other (specify below) below) SVP, Research and Development			
				Amendment, Date Original d(Month/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> </ul>			
GAITHERSE	BURG, MD 2	0878						Form filed by N Person	More than One Re	eporting	
(City)	(State)	(Zip)	Table	e I - Non-D	erivative S	Securi	ties Aco	quired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction I (Month/Day/Ye	ear) Execution any	med on Date, if Day/Year)	Code (Instr. 8)	4. Securi on(A) or Di (D) (Instr. 3,	spose 4 and (A) or	d of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	07/31/2015			Р	892	A	\$ 2.28	1,158 <u>(1)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

## Edgar Filing: NOVAVAX INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships							
	Director	10% Owner	Officer	Other				
Glenn Gregory M C/O NOVAVAX, INC. 20 FIRSTFIELD ROAD GAITHERSBURG, MD 20878			SVP, Research and Development					
Signatures								
/s/ John A. Herrmann III, Attorney-in-Fact		08/04/2015						
**Signature of Reporting Person		Date						
Evelopetion of Door	_	_						

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Includes 892 shares acquired under the Issuer's 2013 Employee Stock Purchase Plan on July 31, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.